Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Bone. 2011 Aug 11;50(2):490–498. doi: 10.1016/j.bone.2011.08.005

Figure 4.

Figure 4

Subcutaneous infusion of risperidone did not alter total body, lean or fat mass, but did reduce femur areal BMD and serum P1NP. Risperidone was administered to female B6 mice by subcutaneously implanted osmotic minipump for four weeks, starting at 8 weeks of age. (A) Lean mass and fat mass were measured by DXA. (B) serumInsulin tolerance test. (C) Glucose tolerance test. (D) Total and femur aBMD were measured by DXA. (E) Serum P1NP and CTx were measured after an overnight fast. Bars represent mean ± standard error of untreated (white) and risperidone treated mice (black). N=5. *p<0.05 by Student’s t-test.